BPI Antibody (3F9)

Product Discontinued

BPI Antibody (3F9) Summary

• Immunogen: The immunogen for this antibody is proprietary information.
• Specificity: 3F9 reacts specifically with full length human natural and recombinant Bactericidal Permeability Increasing protein (BPI)
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: BPI
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunoassay

Reactivity Notes

Human

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: 0.2 um filtered solution in PBS and 0.1% BSA
• Preservative: 0.02% Sodium Azide
• Purity: Protein A or G purified

Alternate Names for BPI Antibody (3F9)

• bactericidal permeability-increasing protein
• bactericidal/permeability-increasing protein
• BPI
• BPIFD1
• CAP 57
• rBPI

Background

The monoclonal antibody 3F9 reacts specifically with full length human natural and recombinant Bactericidal Permeability Increasing protein (BPI). The antimicrobial protein BPI is a 55 kDa protein found in the primary (azurophilic) granules of human neutrophils and has also been detected on surface of neutrophils, small intestinal and oral epithelial cells. BPI is a bactericidal compound that is present in polymorphonuclear cells (PMN) and in lower levels in the specific granules of eosinophils. BPI possesses high affinity toward the lipid A region of lipopolysaccharides (LPS) that comprise the outer leaflet of the gram-negative bacterial outer membrane. Binding of BPI to the lipid A moiety of LPS exerts multiple anti-infective activities against gram-negative bacteria: 1) cytotoxicity via sequential damage to bacterial outer and inner lipid membranes, 2) neutralization of gram-negative bacterial LPS, 3) opsonization of bacteria to enhance phagocytosis by neutrophils. Airway epithelial cells constitutively express the BPI gene and produce the BPI protein and, therefore, BPI may be a critical determinant in the development of LPS-triggered airways disease. Inflammation induced by LPS possibly contributes to the development of rapid airflow decline, a serious and often fatal complication of hematopoietic cell transplantation. Furthermore, a 21 kDa bioactive recombinant fragment of BPI, rBPI21, was shown to confer a survival advantage against invasive pneumococcal disease by binding to the gram-positive bacterial pathogen, pneumolysin. The monoclonal antibody 3F9 recognizes only free BPI and does not interact with BPI that has formed a complex with LPS.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: BPI